Continuation of therapy of secukinumab (SEC): Evidence from a tertiary referral centre
MetadataShow full item record
AbstractA clinical pathway was created to feed information into a clinical audit checklist, and was adopted as the patient-management model for biological therapies. From this, the data was reviewed concerning 41 patients who were receiving SEC between January 2014 and December 2018. The results for the Psoriasis Area Severity Index (PASI) and Dermatology Life Quality Index (DLQI) score which are typically reviewed at baseline and at 16 weeks to assess response to treatment.
CitationAbadie, M. et al. Continuation of therapy of secukinumab (SEC): Evidence from a tertiary referral centre, International Journal of Current Medical And Pharmaceutical Research, Vol. 5, Issue, 04(A), pp. 4114-4118, April, 2019
JournalInternational Journal Of Current Medical And Pharmaceutical Research
Except where otherwise noted, this item's license is described as https://creativecommons.org/licenses/by-nc-nd/4.0/